Literature DB >> 8456100

Site-specific proteolytic cleavage of Ku protein bound to DNA.

S Paillard1, F Strauss.   

Abstract

Ku protein, a relatively abundant nuclear protein associated with DNA of mammalian cells, is known to be a heterodimer with subunits of 85 and 72 kDa which binds in vitro to DNA ends and subsequently translocates along the molecule. The functional role played by this protein in the cell, however, remains to be elucidated. We have observed here that Ku protein, purified from cultured monkey cells, is the target of specific endoproteolysis in vitro, by which the 85 kDa subunit is cleaved at a precise site while the 72 kDa subunit remains intact. This cleavage releases an 18 kDa polypeptide and converts Ku protein into a heterodimer composed of the 72 kDa subunit associated with a 69 kDa fragment from the 85 kDa subunit. The proteolyzed form of Ku protein, denoted Ku', has DNA binding properties similar to those of Ku protein. The proteolytic mechanism, which is inhibited by leupeptin and chymostatin, is extremely sensitive to ionic conditions, in particular to pH, being very active at pH 7.0 and completely inhibited at pH 8.0. In addition, cleavage occurs only when Ku protein is bound to DNA, not free in solution. We suggest that in vivo, such proteolysis might be necessary for Ku protein function at some stage of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8456100     DOI: 10.1002/prot.340150310

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  12 in total

1.  Subnuclear localization of Ku protein: functional association with RNA polymerase II elongation sites.

Authors:  Xianming Mo; William S Dynan
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

2.  Ku86 defines the genetic defect and restores X-ray resistance and V(D)J recombination to complementation group 5 hamster cell mutants.

Authors:  A Errami; V Smider; W K Rathmell; D M He; E A Hendrickson; M Z Zdzienicka; G Chu
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

3.  The C terminus of Ku80 activates the DNA-dependent protein kinase catalytic subunit.

Authors:  B K Singleton; M I Torres-Arzayus; S T Rottinghaus; G E Taccioli; P A Jeggo
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

Review 4.  Interaction of Ku protein and DNA-dependent protein kinase catalytic subunit with nucleic acids.

Authors:  W S Dynan; S Yoo
Journal:  Nucleic Acids Res       Date:  1998-04-01       Impact factor: 16.971

5.  An alternate form of Ku80 is required for DNA end-binding activity in mammalian mitochondria.

Authors:  G Coffey; C Campbell
Journal:  Nucleic Acids Res       Date:  2000-10-01       Impact factor: 16.971

6.  Doxorubicin and octreotide induce a 40 kDa breakdown product of p53 in human hepatoma and tumoral colon cell lines.

Authors:  Zahia Sadji-Ouatas; Malika Lasfer; Sophie Julien; Gérard Feldmann; Florence Reyl-Desmars
Journal:  Biochem J       Date:  2002-06-15       Impact factor: 3.857

7.  OBA/Ku86: DNA binding specificity and involvement in mammalian DNA replication.

Authors:  M T Ruiz; D Matheos; G B Price; M Zannis-Hadjopoulos
Journal:  Mol Biol Cell       Date:  1999-03       Impact factor: 4.138

8.  Exogenously expressed human Ku70 stabilizes Ku80 in Xenopus oocytes and induces heterologous DNA-PK catalytic activity.

Authors:  Jyotshnabala Kanungo
Journal:  Mol Cell Biochem       Date:  2010-01-03       Impact factor: 3.396

9.  Ku and DNA-dependent protein kinase dynamic conformations and assembly regulate DNA binding and the initial non-homologous end joining complex.

Authors:  Michal Hammel; Yaping Yu; Brandi L Mahaney; Brandon Cai; Ruiqiong Ye; Barry M Phipps; Robert P Rambo; Greg L Hura; Martin Pelikan; Sairei So; Ramin M Abolfath; David J Chen; Susan P Lees-Miller; John A Tainer
Journal:  J Biol Chem       Date:  2009-11-05       Impact factor: 5.157

10.  Absence of autoantigen Ku in mature human neutrophils and human promyelocytic leukemia line (HL-60) cells and lymphocytes undergoing apoptosis.

Authors:  A K Ajmani; M Satoh; E Reap; P L Cohen; W H Reeves
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.